Results 211 to 220 of about 89,572 (287)

Integrating antibody–drug conjugates into solid tumor oncology: Current standards and future directions

Cancer, Volume 132, Issue S1, 1 June 2026.
Abstract Antibody–drug conjugates (ADCs) represent a major advance in precision oncology, combining the selectivity of monoclonal antibodies with the cytotoxic potency of chemotherapy. By enabling targeted intracellular delivery of highly potent payloads, ADCs aim to maximize antitumor activity while minimizing systemic toxicity. This review summarizes
André Mansinho, Joana Albuquerque, Andreia Lopes, Emiliano Calvo   +3 more
wiley   +1 more source

Impact of patient‐reported taxane‐induced peripheral neuropathy on dose reductions or worsening quality of life in Black women with breast cancer: Analysis from ECOG‐ACRIN EAZ171

Cancer, Volume 132, Issue 11, 1 June 2026.
Abstract Background Black patients with breast cancer experience higher rates of taxane‐induced peripheral neuropathy (TIPN), which may compromise chemotherapy dose delivery and health‐related quality of life (HRQOL). Using the prospective ECOG‐ACRIN EAZ171 trial, the authors examined whether patient‐reported TIPN predicts dose reductions and longer ...
Tarah J. Ballinger, Fengmin Zhao, Guanglong Jiang, Fei Shen, David Cella, John D. Peipert, Kathy D. Miller, Antonio C. Wolff, Angela M. DeMichele, Bryan P. Schneider, Lynne I. Wagner   +10 more
wiley   +1 more source

Testosterone and docetaxel treatment effect on mortality risk in nonmetastatic high‐risk prostate cancer: A predictive biomarker analysis

Cancer, Volume 132, Issue 11, 1 June 2026.
Abstract Background Prostate cancer (PC) arising in patients with low testosterone is often more aggressive and less responsive to androgen deprivation therapy (ADT). This study evaluated whether baseline testosterone group (low vs. normal) modifies the mortality benefit of adding docetaxel to radiation therapy (RT) and ADT in nonmetastatic high‐risk ...
Johnathan Zeng, Ming‐Hui Chen, Jing Wu, Wanling Xie, Praful Ravi, Paul Nguyen, Howard Sandler, Anthony V. D’Amico   +7 more
wiley   +1 more source

Prediction of lymphocyte‐predominant breast cancer using microRNA expression in cytology specimens

Cancer Cytopathology, Volume 134, Issue 6, June 2026.
Abstract Background Tumor‐infiltrating lymphocytes are prognostic and predictive biomarkers of breast cancer; however, conventional assessment is hindered by invasiveness and subjective evaluation, limiting clinical reproducibility. This study investigated the utility of microRNA (miRNA) profiles in predicting lymphocyte‐predominant breast cancer (LPBC)
Azusa Kai, Koji Arihiro, Hideo Shigematsu, Yukari Ohue‐Uchihata, Momoko Nakamura, Ai Amioka, Shinsuke Sasada, Morihito Okada   +7 more
wiley   +1 more source

Chemotherapy-Forward Management of Advanced Prostate Cancer: Taxane Timing, Sequencing and the Real-World Place of Immunotherapy. [PDF]

Cancers (Basel)
Noro T, Utsumi T, Ikeda R, Ishitsuka N, Suzuki Y, Iijima S, Sugizaki Y, Somoto T, Oka R, Endo T, Kamiya N, Suzuki H.   +11 more
europepmc   +1 more source

Delivering Proteins and Enzymes to Solid Tumors Through the Development of Stimuli‐Responsive Nanocarriers

ChemNanoMat, Volume 12, Issue 6, June 2026.
Stimuli‐responsive strategies to achieve controlled release of protein‐based therapeutic agents into solid tumors. Proteins, enzymes, and peptides have long been recognized as valuable therapeutic agents, particularly in oncology. However, their complex chemical structures render them more sensitive than smaller chemotherapeutic drugs.
Guillermo Plaza‐Palomo, Diana Benita‐Donadios, Sandra Jiménez‐Falcao, Alejandro Baeza   +3 more
wiley   +1 more source

A Phase II Study of Docetaxel and Pembrolizumab plus Interleukin 12 Gene Therapy in Nonmetastatic, Anthracycline-Refractory Triple-Negative Breast Cancer (INTEGRAL). [PDF]

Clin Cancer Res
Niravath P, Uzair I, Sun K, Mai H, Guan J, Li M, Deng J, Qian W, Zhou J, Guzman L, Banaglorioso K, Hashmani R, Mathur S, Chang J.   +13 more
europepmc   +1 more source

MITF Gain‐of‐Function Mutation in Metastatic Prostate Cancer: A Rare Finding With Potential Therapeutic Significance

Cancer Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background Prostate cancer is the most common non‐cutaneous malignancy in men and remains a leading cause of cancer‐related mortality, particularly in aggressive variants. These tumors are usually associated with alterations in TP53, RB1, and PTEN.
Paul J. Pecorin, Nyembezi Dhliwayo, Matthew Demetrious, Ludimila Cavalcante, Veronica Rodriguez‐Bravo, Josep Domingo‐Domenech, Thomas Westbrook   +6 more
wiley   +1 more source